New PMJAY Eligibility Rules Sideline Veteran Oncologists, Sparking Fears of Treatment Delays

MUMBAI — A recent regulatory shift under India’s flagship health insurance scheme, Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PMJAY), is creating a quiet but profound crisis in cancer care. New eligibility requirements are effectively barring hundreds of experienced, fellowship-trained cancer specialists from treating patients under the scheme, a move that experts warn could choke access to oncology services in an already strained healthcare system.

The change, rooted in a strict interpretation of National Medical Commission (NMC) super-specialty degree rules, applies even to veteran surgeons who have spent decades operating at premier institutions like Tata Memorial Hospital and AIIMS Delhi. As hospitals begin removing these specialists from PMJAY rosters, the burden of this “regulatory deadlock” is falling squarely on India’s most vulnerable patients.

The Credentialing Pivot: Degrees vs. Decades of Experience

At the heart of the controversy is a requirement that oncologists must hold NMC-recognized super-specialty degrees—specifically DM (Doctorate of Medicine), MCh (Magister Chirurgiae), or DrNB (Doctorate of National Board)—to perform PMJAY-linked procedures.

While this sounds like a standard move toward quality control, it overlooks a historical reality: until the early 2000s, formal DM and MCh seats in oncology were exceedingly rare. For decades, the gold standard for oncology training in India was the structured fellowship. Surgeons and physicians would complete their post-graduation (MS or MD) and then undergo three or more years of rigorous, hands-on training at apex cancer centers.

Dr. Hemish Kania, a Surat-based oncologist who has been tracking the impact of these rules, estimates that more than 300 fellowship-trained specialists across several states have already been blocked from PMJAY rosters.

“Many of these doctors have taught the very students who now hold the ‘recognized’ degrees,” says a representative from the Indian Association of Surgical Oncology. “To disqualify them retrospectively is to ignore thirty years of clinical excellence and institutional building.”

A Growing Workforce Gap

The timing of this restriction is particularly precarious. India’s cancer burden is staggering:

• 1.5 million: New cancer cases detected annually.

• 4,000: Total number of surgical oncologists nationwide.

• 1 per million: The approximate ratio of medical oncologists to the general population.

In many tier-II and tier-III cities, the private sector provides the bulk of specialized oncology care through PMJAY empanelment. When local specialists are barred from the scheme, the impact is immediate. If four out of six surgeons in a city like Nashik or Patna are suddenly ineligible to bill PMJAY, the remaining two specialists face massive backlogs.

For a cancer patient, time is the most critical variable. Studies, including a 2024 report in The Lancet Regional Health – Southeast Asia, show that PMJAY enrollment significantly increased the likelihood of patients starting treatment within 30 days of diagnosis. Experts fear this progress may now be reversed.

The Regulatory Deadlock

The National Health Authority (NHA), which manages PMJAY, maintains that it empanels hospitals, not individuals. However, NHA CEO Dr. Sunil Kumar Barnwal has indicated that doctor qualifications fall under the mandate of the NMC.

Meanwhile, the NMC has emphasized the need for standardized super-specialty degrees to ensure a uniform quality benchmark across the country. While this goal is supported by many in the medical community as a forward-looking policy, the lack of a “grandfather clause” for experienced fellowship-trained doctors has created a “catch-22.”

“I returned to my hometown in Uttar Pradesh after a three-year fellowship at Tata Memorial to fill a gap in head-and-neck cancer care,” shared one 42-year-old surgeon who requested anonymity. “Now, I am told I cannot operate on PMJAY patients. My patients are forced into longer queues at government hospitals or must travel hundreds of kilometers to find a ‘degree-holding’ surgeon.”

Public Health Implications and Potential Solutions

The primary argument for the new rule is the standardization of medical education. By mandating DM/MCh degrees, the government aims to create a more structured academic pipeline and ensure that all specialists meet the same rigorous educational criteria.

However, critics argue that the policy lacks “on-the-ground” logic. The Indian Medical Association (IMA) has urged the NHA to consider a hybrid model. This would involve:

1. Experience Weightage: Recognizing fellowships from premier institutions as equivalent for the purpose of PMJAY empanelment.

2. Transitional Clauses: Allowing existing practitioners with a documented track record (e.g., 5-10 years of oncology practice) to continue serving PMJAY patients.

3. Institutional Recognition: Automatically qualifying specialists who have served as faculty or senior residents in recognized regional cancer centers.

What This Means for Patients

For families relying on PMJAY, this rule change could mean:

• Increased Wait Times: Specialized surgeries may see delays of weeks or months.

• Travel Costs: Patients in smaller cities may need to travel to metropolitan “Center of Excellence” hospitals.

• Financial Strain: Families may feel pressured to pay out-of-pocket at private clinics if they cannot find an eligible PMJAY provider nearby.

Looking Ahead

As of April 2026, medical associations continue to lobby the NMC and NHA for a written clarification. Without a policy correction, the oncology workforce—already stretched thin—faces a self-inflicted shortage.

The goal of PMJAY is to provide “health for all,” but as veteran oncologists are sidelined, the path to that goal becomes significantly more difficult for those fighting India’s second-leading cause of death.

References

• Economic Times–Health Desk. “New PMJAY rule bars many cancer specialists from treating patients.” April 6, 2026.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.